The burgeoning field of GLP-1 receptor agonists, celebrated for their transformative impact on obesity and type 2 diabetes (T2D) management,…
Read More
Novel Stem Cell Therapy Protocol Shows Significant Promise for Type 1 Diabetes Treatment, Reversing Disease in Mice.
Scientists at the forefront of regenerative medicine, based at the esteemed Karolinska Institutet and KTH Royal Institute of Technology in…
Read More
Novo Nordisk Launches Oral Ozempic in the US, Revolutionizing Type 2 Diabetes and Cardiovascular Risk Management
The landscape of type 2 diabetes management and cardiovascular risk reduction in the United States has been significantly reshaped with…
Read More
Sanofi Receives FDA Approval to Expand Tzield Use in Children as Young as One Year for Type 1 Diabetes Delay
Sanofi has secured a significant expansion of its U.S. Food and Drug Administration (FDA) approval for Tzield (teplizumab-mzwv), a groundbreaking…
Read More
Novo Nordisk Secures FDA Approval for Awiqli, a Once-Weekly Basal Insulin for Adults with Type 2 Diabetes
The United States Food and Drug Administration (FDA) has granted approval to Novo Nordisk for Awiqli (insulin icodec-abae) injection 700…
Read More
Eli Lilly’s Triple Agonist Retatrutide Achieves Remarkable 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes
Eli Lilly and Company has announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Researchers at the University of Konstanz Identify a New Type of Contactless Magnetic Friction and the Breakdown of Amontons Law
The fundamental understanding of how objects move against one another has remained largely unchanged for more than three centuries. Since…
Read More
Eli Lilly’s Triple Agonist Achieves 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes, Signaling Major Therapeutic Advance
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
